In preclinical biochemical research, maleimidopropionic acid (MPA) serves as the reactive Drug Affinity Complex (DAC) moiety attached to CJC-1295, enabling covalent bioconjugation to circulating serum albumin to dramatically extend systemic half-life. In contrast, CJC-1295 No DAC lacks this linker for rapid receptor kinetics, while PNC-27 operates through a non-hormonal, membrane-active mechanism targeting HDM-2 in oncology assays.
In preclinical biochemical research, maleimidopropionic acid (MPA) serves as the reactive Drug Affinity Complex (DAC) moiety attached to CJC-1295, enabling covalent bioconjugation to circulating serum albumin to dramatically extend systemic half-life. In contrast, CJC-1295 No DAC lacks this linker for rapid receptor kinetics, while PNC-27 operates through a non-hormonal, membrane-active mechanism targeting HDM-2 in oncology assays.
The designation of maleimidopropionic acid (MPA) in peptide synthesis marks a critical structural distinction within growth hormone secretagogue research. In modified tetrasubstituted GHRH (1-29) variants, maleimidopropionic acid is covalently attached to the C-terminal lysine residue to form what is commercially and academically designated as the Drug Affinity Complex (DAC). This maleimide functional group selectively reacts with free thiol groups—specifically the Cys34 residue of serum albumin—forming a stable covalent bond in vivo or in albumin-rich assay media.
Without this maleimidopropionic acid linker, the peptide is designated as CJC-1295 No DAC (also known as modified GRF 1-29). While both sequence variants retain the four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV), the absence of the MPA group drastically alters the pharmacokinetic profile. Researchers evaluating cjc-1295-no-dac observe a biological half-life of approximately 30 minutes in animal models, whereas the maleimidopropionic acid-modified variant exhibits an extended half-life exceeding 6 to 8 days due to persistent albumin binding.
CJC-1295 functions as a synthetic analog of growth hormone-releasing hormone (GHRH), binding selectively to the GHRH receptor (GHRHR) on anterior pituitary somatotrophs. In preclinical animal models, activation of GHRHR stimulates the G-protein coupled receptor cascade, elevating intracellular cyclic adenosine monophosphate (cAMP) and triggering the transcription and pulsatile release of endogenous growth hormone (GH).
Studies evaluating growth hormone secretagogues indicate that CJC-1295 preserves the physiological axis by promoting downstream synthesis of insulin-like growth factor 1 (IGF-1) in hepatic tissues. When comparing secretagogues within our research-peptides catalog, the pulsatile secretion profile induced by short-acting cjc-1295-no-dac mimics natural endogeneous release more closely than continuous GHRHR activation, making it a preferred reference standard for physiological GH secretion assays.
PNC-27 is a synthetic chimeric peptide comprising a membrane-penetration peptide domain (derived from penetratin) attached to an HDM-2 binding domain corresponding to residues 12–26 of the p53 tumor suppressor protein. Unlike GHRH analogs that regulate neuroendocrine signaling, pnc-27 is studied exclusively in oncology and cell membrane dynamics research for its ability to induce selective transmembrane lysis in transformed cells.
In vitro assays demonstrate that PNC-27 targets HDM-2 proteins localized specifically within the cell membranes of cancer cell lines. Upon binding, the peptide undergoes a conformational change that forms transmembrane pores, leading to rapid cell lysis (necrotic cell death) without disrupting healthy non-transformed cells that lack membrane-bound HDM-2. Consequently, PNC-27 belongs to a functional class entirely distinct from endocrine regulators like CJC-1295 or ipamorelin.
Evaluating maleimidopropionic acid CJC-1295 against PNC-27 requires delineating their primary targets, molecular weights, and biological pathways. CJC-1295 with DAC (utilizing maleimidopropionic acid) has a molecular weight of 3647.2 Da (unconjugated), targets GHRHR, and serves as a long-acting endocrine modulator. CJC-1295 No DAC has a molecular weight of 3367.9 Da and is used for acute secretagogue profiling. In contrast, PNC-27 possesses a molecular weight of 3818.4 Da, targets membrane-bound HDM-2, and acts as a cytolytic agent in preclinical cancer models.
When designing comparative protocols in laboratory settings, researchers often contrast GHRH analogs like sermorelin, cjc-1295-no-dac, and ghrp-6 to explore pituitary response curves, whereas pnc-27 is paired with cytotoxic or membrane-disrupting peptides. Understanding these structural and functional divergences ensures appropriate experimental design and selection from our all-peptides inventory.
In vitro and preclinical research demands rigorous analytical verification to guarantee reproducible results. PX1 Research supplies peptides manufactured in US-based, GMP-compliant facilities subject to strict ISO 17025 laboratory testing standards. Every single lot undergoes independent third-party analysis, including Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity exceeds 99.0%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight.
Furthermore, biological assays sensitive to bacterial contamination require verification of endotoxin limits. PX1 Research subjects all peptide lots to Limulus Amebocyte Lysate (LAL) testing, guaranteeing endotoxin levels remain under 0.01 EU/mg. Complete, lot-specific Certificates of Analysis (COAs) containing raw HPLC chromatograms and mass spectra are publicly accessible for every compound. For high-throughput laboratory needs, institutional research accounts can access dedicated support via our wholesale portal.
Proper reconstitution protocols are vital to maintain the structural integrity of lyophylized research peptides. Maleimidopropionic acid-modified CJC-1295 and CJC-1295 No DAC should be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline depending on assay requirements. The diluent should be introduced gently along the glass vial wall, allowing the lyophilized cake to dissolve without aggressive vortexing, which can induce mechanical shear and peptide aggregation.
Because the maleimidopropionic acid moiety is reactive toward free sulfhydryl groups, assays involving CJC-1295 with DAC must account for background thiol concentrations in culture media or serum additives. PNC-27 should similarly be dissolved in buffered aqueous solutions (such as PBS, pH 7.4) tailored to cell culture tolerance. Following reconstitution, working aliquots should be prepared immediately to avoid repeated freeze-thaw cycles.
Lyophilized peptides from PX1 Research are stable at room temperature for short-term transit, supported by our same-day shipping operations from dispatch facilities in California and Arizona. Upon receipt in the laboratory, unopened lyophilized vials must be stored at -20°C for medium-term storage (up to 12 months) or -80°C for long-term storage to prevent desamidation or oxidation.
Reconstituted liquid solutions of CJC-1295 No DAC or PNC-27 remain stable at 2°C to 8°C for up to 30 days when formulated with bacteriostatic preservatives. For non-preserved aqueous solutions, reconstituted aliquots should be frozen immediately at -20°C and used within single-use experimental runs. Detailed storage guidelines across all product classes are available in our ghrh-analogs-guide and comprehensive research knowledge base.
When deploying CJC-1295 variants or PNC-27 in experimental models, researchers must tailor culture and dosing conditions to the peptide's chemical kinetics. For CJC-1295 containing maleimidopropionic acid, in vitro cell culture studies requiring free peptide activity may experience altered kinetics if fetal bovine serum (FBS) containing bovine serum albumin (BSA) is present, as rapid bioconjugation to BSA occurs within minutes.
Conversely, when utilizing cjc-1295-no-dac in receptor-binding microarrays or acute pulse-stimulation assays, the absence of albumin binding allows direct, predictable ligand-receptor interaction. For PNC-27 studies, researchers measuring cell viability (e.g., LDH release assays or MTT assays) should account for membrane-disruptive timelines, which typically induce membrane permeability within 1 to 4 hours post-exposure.
What is the role of maleimidopropionic acid in CJC-1295?
Maleimidopropionic acid (MPA) acts as the Drug Affinity Complex (DAC) reactive group attached to the C-terminus of CJC-1295. It enables covalent binding to the Cys34 residue of serum albumin, significantly extending the peptide's biological half-life in laboratory models.
How does CJC-1295 No DAC differ from CJC-1295 with maleimidopropionic acid?
CJC-1295 No DAC lacks the maleimidopropionic acid linker. As a result, it does not bind covalently to serum albumin, exhibiting a much shorter clearance half-life (~30 minutes) compared to the extended half-life (>6 days) of the MPA-modified CJC-1295.
What is the primary mechanism of action of PNC-27 in research?
PNC-27 is a chimeric research peptide that binds to HDM-2 membrane proteins expressed on transformed cancer cells, inducing selective transmembrane pore formation and cell lysis in preclinical in vitro models.
Why is maleimidopropionic acid cjc-1295 used in bioconjugation studies?
Researchers utilize maleimidopropionic acid CJC-1295 to study extended pharmacokinetics, sustained growth hormone release profiles, and albumin-directed bioconjugation chemistry in animal models.
Can PNC-27 and CJC-1295 No DAC be used interchangeably in laboratory assays?
No. CJC-1295 No DAC is a GHRH receptor agonist involved in neuroendocrine signaling and GH stimulation, whereas PNC-27 is a cytolytic peptide targeting HDM-2 for cell membrane integrity research.
How does PX1 Research verify the purity of CJC-1295 and PNC-27?
Every lot is manufactured in US facilities and analyzed by independent third-party laboratories using RP-HPLC to verify purity above 99.0% and ESI-MS to confirm exact molecular mass.
What are the endotoxin standards for CJC-1295 and PNC-27 from PX1 Research?
PX1 Research mandates strict Limulus Amebocyte Lysate (LAL) testing on all lots, ensuring endotoxin levels remain below 0.01 EU/mg for optimal cell culture compatibility.
How should CJC-1295 No DAC be reconstituted for laboratory use?
Reconstitute lyophilized CJC-1295 No DAC using sterile bacteriostatic water by allowing the solvent to run down the inner vial wall, swirling gently until completely dissolved without vortexing.
What storage conditions maintain the stability of lyophilized CJC-1295?
Unopened lyophilized CJC-1295 should be stored at -20°C for medium-term laboratory storage or -80°C for long-term preservation away from light and moisture.
Does PX1 Research offer bulk quantities for institutional research?
Yes, PX1 Research provides high-purity research peptides with lot-traceable COAs for bulk and institutional inquiries through our dedicated wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.